No DEA rescheduling movement follows today's signals; any ibogaine veteran-access push stays confined to foreign clinics or research exemptions.

Ibogaine, a psychedelic derived from an African plant that shows promise for treating opioid addiction and PTSD (post-traumatic stress disorder) in veterans, carries serious heart risks and is classified as a Schedule I drug (meaning the DEA — the US Drug Enforcement Administration — considers it to have no accepted medical use and high abuse potential). Despite advocacy efforts and some promising research, the DEA is not moving to reclassify it, and veterans seeking treatment must travel to clinics in Mexico or other countries, or join narrowly approved research programs. That's unlikely to change soon.

Ibogaine's cardiac risk and Schedule I status keep it offshore. Enforcement posture doesn't shift on preliminary trials or advocacy pressure.